Purpose of this Study
We are doing this study to find out if an experimental drug called XmAb819 (the study drug) is a safe and effective treatment for clear cell renal cell carcinoma (ccRCC).
Who Can Participate?
Eligibility
Adults ages 18+ who:<ul>
<li>Are diagnosed with ccRCC</li>
<li>Have not improved after receiving standard therapy</li></ul>
For more information about who can join this study, please contact the study team at 919-681-6468.
<li>Are diagnosed with ccRCC</li>
<li>Have not improved after receiving standard therapy</li></ul>
For more information about who can join this study, please contact the study team at 919-681-6468.
What is Involved?
If you choose to join this study, you will:<ul>
<li>Get the study drug as either an intravenous infusion (IV) or as an injection under your skin</li>
<li>Have a tumor biopsy</li>
<li>Have physical exams, blood draws, and give urine samples</li>
<li>Have imaging scans (CT and/or MRI)</li>
<li>Have heart tests (ECG)</li></ul>
<li>Get the study drug as either an intravenous infusion (IV) or as an injection under your skin</li>
<li>Have a tumor biopsy</li>
<li>Have physical exams, blood draws, and give urine samples</li>
<li>Have imaging scans (CT and/or MRI)</li>
<li>Have heart tests (ECG)</li></ul>
Study Details
Full Title
A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma
Principal Investigator
Christopher
Hoimes
Protocol Number
PRO00111480
NCT ID
NCT05433142
Phase
I
Enrollment Status
Open to Enrollment